Sonendo, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sonendo, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $33.20M | Mar 26, 2025 |
| FY2023 | Dec 31, 2023 | $43.87M | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $41.66M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $33.20M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $23.35M | Mar 23, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $31.70M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $34.63M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $41.66M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $33.20M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $23.35M | Mar 23, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $11.84M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $4.67M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $10.48M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $8.34M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.89M | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($28.03M) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | ($60.92M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($57.05M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($48.50M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($46.67M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($29.37M) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | ($59.27M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($58.20M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($44.41M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($42.80M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.76M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $10.44M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $16.78M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $18.57M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $20.46M | Mar 23, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $54.02M | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $51.91M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $33.91M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $26.70M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($24.65M) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | ($46.06M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($61.07M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($48.61M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($38.54M) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $161.0K | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $929.0K | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.36M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $638.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $916.0K | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $31.27M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $78.16M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $137.29M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $115.50M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $76.14M | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $26.07M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $49.74M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $55.33M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $43.44M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $48.69M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.19M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $28.42M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $81.96M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $72.06M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($253.89M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($208.91M) | Mar 23, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $8.45M | Mar 11, 2024 |
| FY2023 | Dec 31, 2022 | $8.45M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $8.45M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $8.45M | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($458.05M) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | ($430.01M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($369.09M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($312.04M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($263.55M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.23M | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | $14.01M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $17.67M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $84.64M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $51.72M | Mar 23, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.44M | Mar 26, 2025 |
| FY2023 | Dec 31, 2023 | $40.00M | Mar 11, 2024 |
| FY2022 | Dec 31, 2022 | $40.00M | Mar 8, 2023 |
| FY2021 | Dec 31, 2021 | $30.00M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (59) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | (129) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (59) | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | (129) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 427,330 | Mar 26, 2025 |
| FY2024 | Dec 31, 2023 | 317,737 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 49.97M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 26.34M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 1.20M | Mar 23, 2022 |